Literature DB >> 32060632

Screening of characteristic biomolecules related to bladder cancer based on construction of ceRNA regulation network.

Yan Sun1, DongYan Zhu2, HongJian Xing3, Yi Hou4, Yan Liu5.   

Abstract

OBJECTIVES: The purpose of this study is to screen bladder cancer-associated biomarkers by combining lncRNA, miRNA, and mRNA expression profile of bladder cancer, and to explore bladder cancer-associated tumor markers by constructing a ceRNA regulation network.
METHODS: Bladder cancer mRNA and miRNA samples were downloaded from the TCGA database; the lncRNA and mRNA detected in the RNA-seq expression profile were identified using the HUGO Gene Nomenclature Committee database.
RESULTS: Screening for significant differentially expressed RNA resulted in 1693 mRNAs, 66 lncRNAs, and 130 miRNAs. Then, the significant differently expressed RNAs from the screening were subjected to annotation analysis of GO functional nodes and KEGG signaling pathways. A ceRNA regulation network consisting of lncRNA-miRNA-mRNA was constructed by synthesizing lncRNA-miRNA and miRNA-mRNA. Finally, a ceRNA regulation network consisting of two lncRNAs, one miRNA, and three mRNAs was obtained. KM remodeling curve analysis was performed for each factor.
CONCLUSIONS: In bladder cancer tumor samples, samples down-regulated by LINC01198, PPTRD-AS1, has-miR-216a, SEMA3D, EPHA5, and DCLK1 had a good overall survival prognosis, indicating that these several characteristic target molecules were found to be high-risk factors for bladder cancer tumors.

Entities:  

Keywords:  Bladder cancer; Prognosis; Risk factors; ceRNA regulation network

Year:  2020        PMID: 32060632     DOI: 10.1007/s00345-020-03086-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  3 in total

1.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

Review 2.  Research progress of oncogene and tumor suppressor gene in bladder cancer.

Authors:  X Zhang; C Han; J He
Journal:  Panminerva Med       Date:  2015-01-29       Impact factor: 5.197

3.  A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.

Authors:  Jose I López; Javier C Angulo; Ana Martín; Manuel Sánchez-Chapado; Ana González-Corpas; Begoña Colás; Santiago Ropero
Journal:  APMIS       Date:  2017-06-06       Impact factor: 3.205

  3 in total
  5 in total

1.  Transmembrane Transporter Sema3D Serves as a Tumor Suppressor in Localized Clear Cell Renal Cell Carcinoma.

Authors:  Ruiyang Xie; Jie Wu; Bingqing Shang; Chuanzhen Cao; Xingang Bi; Hongzhe Shi; Jianzhong Shou; Youyan Guan
Journal:  J Oncol       Date:  2022-06-30       Impact factor: 4.501

2.  Identification of lncRNA Biomarkers and LINC01198 Promotes Progression of Chronic Rhinosinusitis with Nasal Polyps through Sponge miR-6776-5p.

Authors:  Xueping Wang; Xiaoyuan Zhu; Li Peng; Yulin Zhao
Journal:  Biomed Res Int       Date:  2022-05-06       Impact factor: 3.246

3.  Explore prognostic biomarker of bladder cancer based on competing endogenous network.

Authors:  Faping Li; Hui Guo; Bin Liu; Nian Liu; Zhixiang Xu; Yishu Wang; Honglan Zhou
Journal:  Biosci Rep       Date:  2020-12-23       Impact factor: 3.840

Review 4.  Role of exosomal competitive endogenous RNA (ceRNA) in diagnosis and treatment of malignant tumors.

Authors:  Mingwen Mao; Jingyu Zhang; Yizhen Xiang; Mengdan Gong; Yongqin Deng; Dong Ye
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

5.  Genome-wide DNA methylation analysis by MethylRad and the transcriptome profiles reveal the potential cancer-related lncRNAs in colon cancer.

Authors:  Guixi Zheng; Yuzhi Zhang; Hongchun Wang; E Ding; Ailin Qu; Peng Su; Yongmei Yang; Mingjin Zou; Yi Zhang
Journal:  Cancer Med       Date:  2020-09-01       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.